Icatibant Aguettant

Icatibant, the active ingredient in Icatibant Aguettant, is a bradykinin B2 receptor antagonist presented as a solution for injection for subcutaneous use. It treats hereditary angioedema caused by C1 inhibitor deficiency in patients requiring acute attack management.

GNH USA supplies Icatibant Aguettant as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Icatibant acts on the bradykinin pathway to relieve swelling in hereditary angioedema.

- Hereditary angioedema (C1‑INH deficiency): provides rapid reduction of edema during acute attacks. - Acute hereditary angioedema attacks: alleviates symptoms within minutes of administration. - Hereditary angioedema types I and II: effective in both subtypes for emergency treatment.

Icatibant may cause a range of adverse reactions following subcutaneous injection.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or erythema: localized skin redness. - Swelling at injection site: transient local edema. - Nausea: occasional gastrointestinal upset. - Headache: mild to moderate intensity. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, urticaria, or anaphylaxis. - Severe hypotension: sudden drop in blood pressure. - Angioedema of the face or throat: may compromise airway. - Infection at injection site: signs of cellulitis. - Thrombocytopenia: reduced platelet count. - Cardiovascular events: rare cardiac complications.

When prescribing Icatibant, clinicians should consider several safety aspects.

- Renal impairment: monitor renal function and adjust use if needed. - Hepatic impairment: use with caution in patients with liver disease. - Pregnancy: safety not established; use only if benefit outweighs risk. - Concomitant ACE inhibitors: may reduce therapeutic effect. - Known hypersensitivity: contraindicated in patients with allergy to icatibant or excipients. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines that affect the bradykinin system or cardiovascular parameters.

Major Interactions (Avoid): - ACE inhibitors: may diminish icatibant efficacy. - Angiotensin receptor blockers: similar potential reduction in effect. - C1‑inhibitor concentrate: concurrent use not recommended.

Moderate Interactions (Monitor Closely): - Diuretics: monitor blood pressure for additive hypotensive effects. - Other bradykinin pathway modulators: assess for overlapping actions. - Antihistamines: may mask early signs of hypersensitivity.